Compare Cassava Sciences Inc (FLNA) vs Hilton Hotels Corporation Common Stock (HLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Hilton Hotels Corporation Common Stock — how do they compare? Cassava Sciences Inc trades at $1.08 (market cap $53.14M), while Hilton Hotels Corporation Common Stock trades at $323.12 (market cap $74.78B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 1407.2× Cassava Sciences Inc's market cap, and Hilton Hotels Corporation Common Stock pays a 0.18% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | HLT | |
|---|---|---|
Market Cap | $53.14M | $74.78B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $350.22 |
52-Week Low | $1.09 | $256.75 |
Enterprise Value | -$33.43M | $87.27B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Hilton Worldwide (HLT) trades at $325.86, showing stability with no recent price change. The stock exhibits bearish technical signals but maintains strong fundamentals, including consistent revenue growth to $12.04B in 2025 and a net income margin of 12.56%. Recent earnings have consistently beaten expectations, and analyst sentiment remains positive with a 55.1% buy rating. Key developments include brand expansions and partnerships, such as the launch of Undergraduate by Hilton and collaborations with Big Brothers Big Sisters, highlighting ongoing growth initiatives.
The outlook for HLT is cautiously optimistic, driven by solid earnings performance and strategic growth, though elevated debt levels and bearish technical indicators pose risks. Investors should weigh the company's strong market position against potential volatility from macroeconomic factors and competitive pressures in the hospitality sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →
